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Abstract
Vaccination is an effective means for prevention of the progression and spread of influ-
enza virus infection. Nonetheless, there is a risk of adverse reactions, such as pain and 
fever, during the vaccination. In addition, because people from a wide age range, that is, 
from children to the elderly, are inoculated with vaccines, safety confirmation of these 
vaccines is important. Safety assessments of a vaccine, in the form of quality controls, 
have been carried out on animals. For example, the abnormal toxicity test is based on 
body weight changes as a toxicity index, and the leukopenic toxicity test can evaluate 
hematological toxicity. Meanwhile, since the 2000s, safety evaluation of drugs and chemi-
cals by the genomic approach has been conducted frequently. The benefits with respect 
to safety evaluation are high sensitivity and abundant information about toxicity profiles. 
In this chapter, we describe the genes that are helpful as safety assessment markers and 
their usefulness for safety testing and vaccine development. In addition, this information 
may provide toxicity profiles, help understand the reactogenicity of nasal vaccines or 
adjuvants, and explain the prospects of genomic analyses in the development of novel 
vaccines and adjuvants.
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1. Introduction
The current toxicological assays for chemicals and biological therapeutics (biologicals) involve 
high costs, are time-consuming, and require a large number of animals. Thus, such a project 
becomes a substantial investment in the development of a drug or biological therapeutic [1, 
2]. There is a need to improve these preexisting safety-testing strategies.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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The microarray technology was recognized in the toxicology research community after its 
introduction in the 1990s [3–5]. Subsequently, toxicological studies using the microarray tech-
nology have given rise to a new field termed toxicogenomics [6]. By integrating the genomic 
technology and bioinformatics, toxicogenomics has garnered a great deal of attention as an 
alternative means of addressing drug safety by studying the fundamental molecular mecha-
nism of toxicity, which was difficult to detect with conventional toxicological methods [6]. In 
fact, microarray-based toxicogenomics remains a major breakthrough. Using microarrays, we 
can monitor the expression levels of tens of thousands of genes at the same time and evaluate 
gene expression profiles altered by various compounds or changes in gene expression pro-
files associated with different physiological conditions. Moreover, testing a large number of 
genes together gives the opportunity to identify genetic patterns and signatures that provide 
unique insights into drug toxicity, which are difficult to obtain by conventional animal-based 
techniques [7]. Thus, toxicogenomics is expected to revolutionize the traditional approaches 
to toxicity assessment and has been considered a paradigm shift in toxicology. To date, many 
studies have revealed the value of toxicogenomics [8–15]. For example, it has been suggested 
that toxicogenomic biomarkers can identify drug candidates that are more likely to cause 
toxicity in susceptible patient populations despite the lack of conventional toxicity indica-
tors, such as hematological parameters, body weight changes, blood biochemical data, and 
histopathological data, which are examined in preclinical studies [16, 17]. Similarly, more 
sensitive biomarkers for the detection of early toxicity can be analyzed at “subtoxic doses” of 
a candidate therapeutic agent, where the injury is at the genetic level, but does not occur at the 
phenotypic level or cannot be detected by clinical-chemistry measurements [18].
Just as chemical and synthetic drugs, biological therapeutics are evaluated for their toxicity by 
safety tests involving animal experiments, as part of preclinical studies. In addition, to guarantee 
the quality and homogeneity of the preparation, a portion of the biological preparation is sub-
jected to toxicity tests for each lot [19, 20]. These toxicity tests are based on the aforementioned 
conventional assays, and phenotypic alterations such as body weight changes, hematological 
changes, pathological changes, and similar parameters are the evaluation criteria [19, 21]. Tests 
of the safety and quality control of vaccines include the abnormal toxicity test (ATT, also known 
as a general toxicity test) [21], and the leukopenic toxicity test (LTT) [19]. In all preclinical trials, 
in addition to these tests, a pathological examination is carried out. Although these tests have 
historically been practiced for a long time, it is expected that genomics techniques will be incor-
porated into these tests to improve their sensitivity and to obtain information on toxicity. For 
biologicals, however, toxicity studies using the genomics technology have not yet been actively 
carried out, when compared to the testing of chemical and synthetic drugs.
Therefore, we have been using the genomics technology to search for vaccine safety assess-
ment markers since the late 2000s. In particular, we have been conducting research on the 
use of genomics technology for studying pertussis vaccine [22, 23], Japanese encephalitis vac-
cine [24], and influenza vaccine [25]. This chapter provides an introduction to the genom-
ics technology in the safety assessment and quality control evaluation of influenza vaccines 
and describes a new evaluation method involving the biomarkers obtained by the genomics 
technology.
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2. Current vaccine safety tests
This section describes the lot release safety and quality control testing methods implemented 
for the influenza vaccine. The ATT has been conventionally conducted as an animal-based test 
to evaluate the contamination by phenol, which is used in the process of inactivating endotox-
ins, viruses, and bacteria [26, 27]. The method of ATT is simple: 5 mL of a sample is injected 
into the abdominal cavity of a guinea pig, and its survival and 7-day body weight changes are 
measured [19]. It has been suggested that these 7-day body weight changes reflect the biologi-
cal activity of the vaccine. Indeed, if the animals were inoculated with a different type of influ-
enza vaccine, their body weight changes would show different profiles [21]. The whole-particle 
inactivated influenza vaccine (WPV) that has high reactogenicity [28]. Nevertheless, it causes 
highly frequent adverse reactions, such as pain, swelling, and fever [29]; on the other hand, 
the hemagglutinin-split influenza vaccine (HAV), whose effectiveness is inferior to that of the 
WPV [28], has been reported to cause almost no adverse reactions [29]. The current seasonal 
influenza vaccines are based on the HAV, and the WPV is manufactured only as a pandemic 
vaccine. This approach also includes avoiding adverse reactions caused by WPVs. Therefore, 
the WPV also serves as a toxicity index in the quality control testing of the HAV by the LTT, 
which is described later.
The LTT is a safety test that assesses the leukopenic toxicity induced by the WPV as a toxicity 
index [19]. In this method, mice are inoculated with 0.5 mL of a WPV as a toxicity reference 
vaccine, and the leukopenic activity rate induced by the WPV at that time point is set to 100% 
leukopenic activity. At that time point, the test sample confirms whether the leukopenic activity 
rate is within 20% or not. The test criterion is as follows: the leukopenic activity rate should be 
less than 20% of the toxicity control. On the other hand, the ATT is an assay that evaluates the 
body weight loss of guinea pigs, and the transition during their recovery. When the same exper-
iment was carried out in rats, WPV-injected rats showed a severe body weight loss, unlike HAV-
injected rats [21]. A vaccine showing a statistically significant body weight loss in a population, 
when compared with a homogeneous preparation, would be rejected in terms of its quality.
Thus, safety and quality of the HAV are mainly ensured by two tests. Safety assessments of 
the HAV have been conducted using WPVs, which is one of the safety indices.
3. The genomic approach to identifying novel biomarkers of 
influenza vaccine safety
The search for new biomarkers that can reflect the bioactivity assessed in the ATT and LTT 
was conducted by performing comprehensive gene expression analyses on major organs via 
the microarray technology [25]. Inactivated influenza vaccines have been widely used for 
preventing infections and the spread of infections; they can roughly be subdivided into two 
types: the HAV and WPV [30]. The HAV mainly contains hemagglutinin (HA). This type of 
vaccine has no strong bioactivity; it does not contain substances other than HA proteins that 
act as antigens, thereby leading to no adverse reactions. Nevertheless, their ability to induce 
Genomic Approaches Enable Evaluation of the Safety and Quality of Influenza Vaccines…
http://dx.doi.org/10.5772/intechopen.76361
115
Symbol Official full name Accession
Cxcl11 Chemokine (C-X-C motif) ligand 11 NM_019494
Cxcl9 Chemokine (C-X-C motif) ligand 9 NM_008599
Zbp1 Z-DNA binding protein 1 NM_021394
Mx2 MX dynamin-like GTPase 2 NM_013606
Irf7 Interferon regulatory factor 7 NM_016850
Lgals9 Lectin, galactoside-binding, soluble, 9 NM_010708
Ifi47 Interferon gamma inducible protein 47 NM_008330
Tapbp TAP binding protein (tapasin) NM_001025313
Csf1 Colony stimulating factor (macrophage) NM_007778
Timp1 Tissue inhibitor of metalloproteinase 1 NM_001044384
Trafd1 TRAF type zinc finger domain containing 1 NM_001163470
Lgals3bp Lectin, galactoside-binding, soluble, 3 binding protein NM_011150
Psmb9 Proteasome (prosome and macropain) subunit, beta type, 9 NM_013585
C2 Complement component 2 NM_013484
Tap2 Transporter 2, ATP-binding cassette, sub-family B (MDR/TAP) XM_006525355
Ifrd1 Interferon-related developmental regulator 1 NM_013562
Psme1 Proteasome (prosome and macropain) activator subunit 1 NM_011189
Ngfr Nerve growth factor receptor NM_033217
Table 1. Marker genes for safety evaluation of influenza vaccines.
antibody production is considered insufficient to prevent the progression of influenza virus 
infection [30]. Historically, however, vaccines have been more effective than the existing 
split vaccines. The WPV is considered effective against influenza virus infections. This type 
of vaccine contains the whole influenza virus particle, including lipid and single-stranded 
RNA, and therefore, drives various immune responses. On the other hand, various WPV-
induced immune responses also cause adverse reactions in humans [29]. Therefore, although 
WPV is a highly effective vaccine, it has lately not been employed as a seasonal influenza 
vaccine and is only partially manufactured as a pandemic influenza vaccine. We have carried 
out the searches for safety assessment marker genes of the HAV using two types of vaccines: 
the WPV and split influenza vaccine (SV). The WPV has high reactogenicity (effectiveness 
and toxicity) and therefore serves as a toxicity reference. The SV has low reactogenicity and 
frequency of adverse reactions and is therefore employed as a safety control. As a result, the 
clearest clustering of gene expression patterns in the lungs of animals by different types of 
vaccines was obtained [25]. In particular, the gene expression patterns in the lungs differed 
between the SV-treated and WPV-treated animals. Furthermore, the gene expression levels, 
which showed large differences between the SV- and WPV-treated animals, were estimated. 
As a result, 18 genes expressed in the lungs were identified as biomarker genes (Table 1) [25]. 
Influenza - Therapeutics and Challenges116
Functionally, these biomarker genes tend to correlate with the white blood cell (WBC) count 
in the peripheral blood of animals (leukopenic toxicity) that were treated with the inactivated 
influenza vaccine [31, 32]. It has been known that intraperitoneal injection of the WPV causes 
leukopenic toxicity in mice, and this bioactivity has been used as an index for the safety 
evaluation of inactivated influenza vaccines in Japan, which is termed the LTT [19]. In addi-
tion, WPV-induced body weight loss may be reflected in biomarker gene expression levels 
[25]. Thus, WPV-like bioactivity assessed by the ATT could be predicted by the expression 
levels of biomarker genes. Furthermore, the biomarker genes can partially measure biologi-
cal activities that cannot be quantitated by means of body weight changes. For example, the 
identified biomarker gene expression increases with leukopenia and weight loss; however, 
some genes show increased expression even in a state without body weight loss and with-
out a decreased WBC count (without leukopenic toxicity) [33]. The SV hardly induces the 
elevated expression of biomarker genes. By contrast, if SVs produced at different manufac-
turing plants were evaluated using the biomarker gene expression levels, variations in their 
quality can be reflected in the expression levels [33]. This variation is not indicated by body 
weight changes or by the WBC count [33]. This case is an example where the gene expression 
level can detect biological reactions that cannot be detected by phenotypic changes. This is 
the advantage of the toxicogenomics technology. Thus, it is likely that the genomics technol-
ogy is also useful for the safety assessment of vaccines. Furthermore, there is a possibility 
that the assay involving the newly identified biomarker genes can be widely adopted as an 
alternative method to the currently popular methods: the ATT and LTT.
4. Safety evaluation of influenza vaccines on the basis of biomarker 
gene expression
The utility of the identified biomarker genes has been verified. For seasonal influenza vac-
cines, the ATT has been regarded as a test for safety and quality control. Therefore, a safety 
assessment of SVs manufactured at four manufacturing plants was conducted by means 
of biomarker gene expression and body weight as parameters (ATT) and by the LTT, with 
a WPV as a control [33]. With respect to phenotypic changes, body weight loss rates of all 
the SVs were found to be equivalent, and leukocyte number reduction was hardly observed 
for the HAVs from all the manufacturers. Nevertheless, in case of one manufacturer’s HAV, 
analyses of the expression of 18 biomarker genes in lungs showed a significant difference 
in gene expression levels from other manufacturers’ HAV [33]. This result suggests that the 
biomarker genes identified by the microarray analysis can capture biological changes that 
cannot be detected by body weight changes and leukocyte number reductions. This finding 
indicates that the analysis of expression of biomarker genes is a more sensitive assay than the 
conventional safety and quality control tests (ATT and LTT). This evaluation method can be 
applied not only to predict the toxicity but also to evaluate the homogeneity among vaccines 
produced in different batches.
Subsequently, the safety assessment of trivalent virosome-type influenza vaccine (Inflexal 
Berna V) currently licensed in several European countries such as Switzerland and Italy was 
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performed by means of the biomarker genes. The virosome-type influenza vaccine is similar 
to the WPV but does not contain viral RNA. Leukopenic reactions were not noticeable when 
the animals were vaccinated with the virosome-type influenza vaccine; however, a body 
weight loss was observed, accompanied by an increase in the expression of some biomarker 
genes [31]. It is thought that some biological activities of this vaccine may be close to those 
of the WPV, because just like the WPV, Inflexal Berna V consists of a virosomal formulation. 
Genes whose increased expression levels were induced by the virosomal type influenza vac-
cine include Tap2 and Psmb9, which are involved in antigen presentation and antigen diges-
tion, suggesting that the antigen-presenting ability is higher for the virosomal-type influenza 
vaccine than for the HAV [31]. Consequently, it is likely that biomarker genes obtained by 
genomic analysis can elucidate the mechanistic details of bioactivity and toxicity.
5. Safety evaluation of the nasal influenza vaccine using biomarker 
gene expression
Nasal vaccines have been attracting attention as promising strategies against influenza virus 
infection. This is because nasal vaccines can predominantly induce mucosal immunity, when 
compared with conventional subcutaneous vaccines or intramuscularly injectable vaccines 
[34]. In nasal vaccines, IgA antibody production and secretion in the bronchial and intranasal 
cavities are observed, and this approach seems to be effective for the prevention of influenza 
infection [35–37]. For this reason, several newly developed vaccines have been designed on 
the premise of nasal inoculation. It is important to develop a safety assessment method for 
nasal vaccines by assays that are different from the conventional intramuscular and subcu-
taneous injections. This is because there are case control studies on the use of the inactivated 
intranasal influenza vaccine, which is composed of influenza antigens in a virosomal formu-
lation with an E. coli-derived LT adjuvant, and the risk of Bell’s palsy in Switzerland [38]. 
Therefore, to determine the relation between the expression of the 18 biomarker genes and the 
safety evaluation of the nasal inoculation influenza vaccine, an assay was devised. Mice were 
nasally inoculated with an influenza vaccine, and biomarker gene expression levels in the 
lungs were analyzed [39]. As described earlier, this biomarker gene has been identified based 
on the gene expression profile obtained when the vaccine was inoculated intraperitoneally. 
After the administration of the nasal influenza vaccines, there was an increase in the WPV-
dependent expression of the biomarker gene; the evaluation of the HAV based on WPV was 
shown to be possible by nasal inoculation and by analysis of marker genes [39]. Furthermore, 
the biomarker expression level positively correlated with lymphoproliferation in nasal-asso-
ciated lymphoid tissue [39], and it was inferred that this formulation induces the activity of 
mucosal immunity. Furthermore, in recent years, the development of an adjuvant-containing 
vaccine has been advanced for the purpose of enhancing the effectiveness of SVs [37]. The 
same trend in nasal vaccines has also been seen [37] because of the ability to induce IgA pro-
duction by SVs alone is not enough to prevent infection with an influenza virus. Therefore, 
there has been active development of adjuvanted influenza vaccines. Although adjuvants 
increase the effectiveness of vaccines, strong adjuvant bioactivity is thought to lead to toxicity. 
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The strong bioactivity of the adjuvant will ensure increased effectiveness of vaccines. In some 
cases, however, highly reactogenic adjuvants can cause toxicity in humans. For example, poly 
I:C is known to function as an excellent vaccine adjuvant. On the other hand, it is known to 
cause exothermic reactions and cytokine storms [40–42]. Additionally, in the past, poly I:C has 
been discontinued due to adverse reactions such as a fever and arthritis in clinical trials [40]. 
Even other adjuvants such as R848, a Toll-like receptor (TLR)7/8 agonist, are known to cause 
cold-like symptoms, including a fever [43–45]. Such compounds are excellent in terms of 
enhancing the effectiveness of the vaccine; however, the risk of developing toxicity remains 
high. Therefore, we hypothesized that the expression of 18 biomarker genes could be applied 
to the safety assessment of adjuvanted vaccines. The objective of this safety test is to identify 
an adjuvant that has high reactogenicity and toxicity such as poly I:C and R848. The risks of 
adverse reactions caused by adjuvanted vaccines as test products were compared with those 
of the WPV. In the case of a nasal vaccine, expression of some biomarker genes was higher 
when animals were inoculated with the TLR9 agonist CpG K3-adjuvanted HAV, than when 
the animals were inoculated with the HAV alone [39]. Nonetheless, the marker gene expres-
sion levels were markedly lower than those of the WPV. Thus, the CpG K3 adjuvant did not 
have high reactogenicity accompanied by toxicity. The CpG K3 adjuvant is under develop-
ment for use with malaria vaccines [46]; no adverse reactions have been reported so far. The 
authors of these reports presumed that the risk of toxicity would not be high in humans. 
Currently, the authors are working on building a database for constructing an adjuvant evalu-
ation system based on an influenza vaccine that includes various adjuvants including poly I:C 
and R848, an oil/water emulsion adjuvant, and various other TLR-related adjuvants.
6. Development of an alternative assay for the leukopenic toxicity 
test based on biomarker gene expression
The biomarker genes for the safety assessment of an influenza vaccine are characterized 
by the biological activity that can be detected by the ATT and LTT. Specifically, biomarker 
gene expression levels and the WBC count with body weight changes show a negative cor-
relation [31]. Momose et al. (2015) reported that a virosomal influenza vaccine caused only a 
body weight loss and did not cause leukopenia; however, some of the marker genes showed 
increased expression levels at that time point [31]. In other words, it seems that all the marker 
genes cannot respond uniformly via the same mechanism of action. Therefore, we considered 
whether the leukocytopenic activity could be evaluated with the expression of the marker 
genes responsible for the leukopenic activity, and we searched for biomarker genes associated 
with leukocytopenic activity. Furthermore, we devised a method for WBC count-predicting 
systems involving only the biomarker gene expression levels. If this method is established, it 
will be possible to set up the WBC number prediction using the biomarker gene expression 
and body weight loss evaluation by the ATT in one test system. This strategy will reduce the 
number of animals required and shorten the testing duration. We tried to identify the genes 
useful for the prediction of the WBC count from the biomarker gene set by multiple linear 
regression analysis and a stepwise method [32]. In the multiple regression analysis method, 
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Predictor variable Model 1 Model 2 Model 3 Model 4
β β β β
Intercept 2141.2 5390.6 4222.5 5293.7
C2 — — — 502.8
Trafd1 −3196.2 −2886.6 — −1131.1
Irf7 — — — −94.7
Csf1 — — — 1118.1
Ngfr −1344.8 — — −360.1
Ifi47 — — — 472.3
Ifrd1 — — — −1628.5
Psme1 4099.9 — — —
Tap2 3084.6 1839.1 — —
Cxcl11 −0.3847 −0.1217 — —
Lgals9 −8.0607 — — —
Zbp1 −197.49 — — —
Cxcl9 — — 1.8226 —
Lgals3bp — — −552.93 —
Tapbp — — 349.20 —
Table 2. Multiple regression by the stepwise forward selection method for the leukopenic reaction prediction model 
(cells/μl blood).
a linear equation expressed by the following formula was derived, and a predicted value was 
calculated. In particular, the leukocyte count of the animals and data on the expression lev-
els of all the biomarker genes were acquired. The animals were inoculated with the WPV or 
HAV, and the expression levels of marker genes and numbers of WBCs were then determined. 
Multiple regression analysis was performed on the acquired data. A linear equation was then 
derived. The regression equation is shown below.
  (Predicted WBC)  =  (intercept) +  β 
1
   x 
1
 +  β 2   x 2 + … + β n   x n (1)
In this equation, “x” is substituted by the marker gene expression that corresponds to its coef-
ficient (β); “n” indicates the number of factors corresponding to the number of selected genes. 
The intercept was used for calculation of the WBC number in the multiple regression analysis.
Precision of the prediction differs depending on the combination of marker genes. Therefore, 
by the stepwise method, a linear equation was derived that contains the combinations of 
marker genes having the highest prediction accuracy. As a result, some gene combinations 
(models) were selected (Table 2). Predicted leukocyte numbers produced by these models 
can predict leukopenia caused by WPVs with high accuracy (Figure 1). Even if the predicted 
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values of individuals are analyzed, the deviation between the predicted value and the mea-
sured value is small [32]. In addition, variations in the WBC count owing to individual differ-
ences are reproduced with high accuracy [32]. Therefore, it was shown that the leukopenic 
activity can be predicted by means of the identified marker gene set. With this method, it is 
expected that it will be possible to carry out WBC count reduction assays and abnormal tox-
icity negative tests by expression analysis of one biomarker gene. As mentioned in the pre-
vious section, the development of adjuvanted vaccines has advanced in recent years. Some 
adjuvants, like WPVs, exert a leukocytopenic activity. Leukopenic activity is also present in 
compounds with an excellent adjuvant activity such as Poly I:C and R848 [43]. Therefore, 
we analyzed the CpG K3 adjuvant, which manifested a slight leukopenic activity according 
to the newly developed multiple regression Equation [32]. As a result, a slight leukopenic 
activity was observed in animals that received the CpG K3 adjuvant in combination with 
the SV. Furthermore, when the expression levels of the marker genes were analyzed, and 
the predicted WBC count was calculated from their expression levels, the leukocyte count 
reduction by the CpG K3 adjuvant could be predicted with high accuracy [32]. At the same 
time, however, it became clear that leukocytosis is unpredictable in this system [32]. When 
the CpG K3 adjuvant was inoculated at low concentrations, the leukocyte count tended to 
Figure 1. Prediction of a leukocyte count reduction by means of marker gene expression levels in mice treated with 
influenza vaccine. In the leukopenic toxicity test (LTT), mice were intraperitoneally injected with 0.5 mL of one of 
influenza vaccines. The dosing of whole-particle inactivated influenza vaccine (WPV) and hemagglutinin-split vaccine 
(HAV) was 15 μg hemagglutinin (HA)/0.5 mL. Poly I:C was reconstituted in an appropriate volume of the HAV solution 
to obtain concentrations of 1, 5, 10, and 20 μg poly I:C per dose. Saline (SA) served as the cssssontrol. Sixteen hours after 
vaccination, blood was collected to assess the numbers of leukocytes, and the lungs were immediately excised. The 
collected lung tissue was subjected to gene expression analyses. The predicted values were calculated via the multiple 
regression equation. The coefficient values and values serving as the intercept are indicated in Table 2. The error bar 
indicates standard deviation.
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increase. This increase in the WBC count could not be predicted from the biomarker gene 
expression levels. The possible reason is that multiple linear regression analysis was per-
formed on the animals inoculated with vaccines with leukopenic activity. The physiological 
association of the extracted biomarker gene with leukopenia could be another reason for this 
phenomenon. We have identified biomarker genes highly correlating with leukocyte counts 
in mathematical terms, ignoring the functions of the genes. There is a report that apoptosis 
of leukocytes caused by type 1 interferons (IFNs) could be a mechanism underlying the 
WBC count reduction by WPVs [47]. The marker gene set contains many genes related to 
type 1 IFN. By contrast, in model 4 (Table 2), more than a half of the genes related to type 
1 IFN were omitted because they lacked predictability. As a result, it is conceivable that a 
correlation cannot be obtained from only a simple expression level because of the time lag 
between gene expression and actual leukocyte depletion; furthermore, a gene itself forms a 
complicated network.
7. Possibility of application of genomic approaches to in vitro safety 
evaluation methods
Currently, safety evaluation and parts of quality control of vaccines are carried out in animal 
experiments. The ATT and LTT are representative tests in this regard; they have been practiced 
for more than 50 years [48]. Due to the nature of the test, the ATT excludes the unintended tox-
icity of the vaccine; the test of lots having reactogenicity different from that of other reference 
lots is a final confirmatory test designed to prevent serious toxicity in humans [21]. Actually, the 
ATT has been incorporated into the lot release of vaccines, especially for inactivated influenza 
vaccines in Japan [19]. On the other hand, tests on animals are being replaced with in vitro evalu-
ation systems involving cultured cells, from the viewpoint of animal welfare and cost [48]. In the 
safety evaluation of chemically synthesized medicines, there has been a notable development: 
human cultured hepatocytes and cardiomyocytes prepared from induced pluripotent stem cells 
[48–52]. The benefit of the in vitro evaluation system is not only the reduction in the number of 
animals used, but also the possibility of using human tissue or fluid samples, so that extrapola-
tion to humans can be expected. For biologicals, a part of the rabbit pyrogen test was replaced 
with an endotoxin quantitative test. Nevertheless, this replacement has not yet been achieved 
for all biologicals. The endotoxin test could not be performed on some preparations because of 
the presence of interfering substances [53, 54]. Therefore, a rabbit pyrogen test has been carried 
out for these biologicals. In this test, the causative agent of the fever has been recognized as the 
endotoxin in some biologicals. Thus, switching to a method of directly quantitating endotox-
ins was introduced as an alternative for the rabbit pyrogen test. Nonetheless, because the ATT 
evaluates the weight loss of animals, it is difficult to determine from body weight changes what 
types of molecular signaling pathways or physiological reactions have been affected. Therefore, 
it has not been easy to develop an in vitro assay as an alternative for the ATT.
We have tried to create a safety evaluation system for an influenza vaccine using the genomics tech-
nology in animal models [22–25]. The marker genes identified in animal experiments are believed 
to be involved in the body weight loss of animals after WPV injection [25]. When considering an 
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alternative assay, phenotypic changes in animals, such as body weight loss, cannot be assessed 
in cultured cells. On the contrary, marker genes linked to these bioactivities can be identified at 
the cultured-cell level. Biomarker genes can make it possible to link cellular data with biological 
reactions observed in animal phenotypes. We are currently working on demonstrating the useful-
ness of marker genes and their expression mechanisms. Most of the marker genes are involved in 
an immune response and are related to type 1 IFN signaling and innate immune responses [39]. 
According to these findings, it is possible that the usefulness of biomarker genes evaluated in ani-
mals can be extrapolated to cultured cells, if such cell lines as peripheral blood mononuclear cells, 
immune cells, and alveolar epithelial cell lines are employed in the assays. If an alternative (in vitro 
method) for the ATT and LTT is developed, it will be possible to secure the safety and quality of 
the current ATT and LTT by animal-free testing. This approach is expected to reduce the number 
of animals tested and to shorten the testing period.
8. Establishment of a new evaluation method for vaccine or adjuvant 
bioactivity based on biomarker gene function
Analysis by the genomics technology can be applied not only to the search for biomarkers but 
also to mechanistic analyses. Besides, it is possible to classify each biological reaction by hier-
archical clustering analysis, according to microarray analysis results. Microarray analysis is the 
most information-rich assay; however, it is inefficient in terms of cost and labor. In the case of a 
clear-purpose test such as safety evaluation and quality control, it is expected that robust results 
will be obtained by using only selected highly important genes for evaluation. Therefore, if we 
consider the function of the genes identified as safety or quality evaluation markers for influ-
enza vaccines, then the biological activity profile of the vaccine may be predicted. For example, 
genes such as Irf7 are induced by type 1 IFN [55], genes such as Psmb9 and Tap2 are involved 
in antigen presentation [56], and Csf1 participates in the activation of monocytes and macro-
phages [57]. Thus, expression levels of these genes could serve as indicators of the mode of 
action and help in the development of a biological activation assessment tool. These genes are 
thought to be involved in innate immunity, in which responses are observed at a relatively 
early time point after vaccination. Indeed, expression of these genes was assayed 16 h after vac-
cination. Therefore, long-term toxicity due to the vaccine (e.g., autoimmune and chronic inflam-
matory reactions) cannot be assessed. Safety evaluation by means of these biomarker genes is 
helpful for the development of adjuvant-containing vaccines. This is because most adjuvants 
are designed to activate the innate immune system. Adjuvants enhance innate immunity via 
cytokine production and activation of antigen-presenting cells; however, strong activation of 
innate immunity causes uncontrollable inflammatory reactions. This problem could lead to a 
fever, pain, and swelling, which appear as adverse reactions. Thus, adjuvants are required to 
have strong innate-immunity–activating effects, but at the same time, good safety. On the other 
hand, it is difficult to distinguish between the effectiveness and safety of vaccines. For example, 
interleukin (IL)-6 and type 1 IFN are important for the induction of adaptive immunity and are 
favorable for vaccine efficacy [58, 59]. Nevertheless, excess production of IL-6 or type 1 IFN 
causes a cytokine storm. Thus, safety can be evaluated with the same biological vector as that 
of effectiveness. In other words, if the factor of effectiveness becomes excessive, toxic effects 
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may appear. We are currently working on establishing a safety assessment system based on 
the WPV as a toxicity indicator [60]. The WPV is an effective and excellent vaccine, but the 
frequency of adverse reactions is high, and currently, it is only rarely used, especially as a pre-
pandemic vaccine. Therefore, we believe that the WPV can be a safety indicator. In other words, 
we think that there is a high probability that adjuvants and vaccines with innate-immunity–
inducing activities that exceed the activity (toxicity) of WPVs will cause adverse reactions [60].
9. Future perspectives of safety evaluation of vaccines and adjuvants
According to the abovementioned concept, various evaluations of adjuvanted vaccines have 
been carried out. Furthermore, we have focused on the functions of biomarker genes. We 
have attempted to compile gene clusters based on the function of each gene. Such an assay is 
currently at the development stage, and further examination of the evaluation method and 
validation should be conducted in the future. Such an assay is considered applicable to the 
development of novel adjuvants.
For the development of low-molecular-weight synthetic drugs, a seed compound having 
a desired bioactivity is searched for by a screening system in compound libraries [61]. For 
promoting adjuvant development, to create as many prominent novel adjuvants as possible, 
finding seed compounds that are likely to become adjuvants is a crucial step in adjuvant 
development. Conventionally, to demonstrate whether a compound has adjuvant activities, 
animals are inoculated with one of the compounds, and the antibody titer and infection pre-
vention rate are then assessed. This evaluation is not as efficient as the seed search and com-
pound screening because the assessment process takes more than 1 month. In contrast, if 
we introduce an evaluation method involving a biomarker gene or genes, then prediction 
of safety and of the biological activity profile for compounds may be achieved in animals or 
cultured cells. Such an assessment may make it possible to search for effective adjuvant seeds 
that are safer than WPVs and more effective than the HAV.
10. Extrapolation of the safety evaluation results to humans 
according to biomarkers’ gene function
Given that the evaluation of the quality and safety of vaccines assumes a reaction with 
humans, the evaluation result must reflect the human biological response. Generally, there 
are species differences in immunological responses between humans and rodents. Therefore, 
it is necessary to interpret the results carefully.
In case of safety evaluations based on genomic analyses, estimating the difference between 
experimental animals and humans with reference to the function of genes may be partially pos-
sible. For example, in the case of the WPV, leukopenic toxicity and body weight loss are observed 
in rodents, but these effects cannot be verified in humans. Nevertheless, at the gene level, if a 
gene is conserved among species, it is possible to estimate whether similar biological reactions 
can be observed between humans and animals. All our identified marker genes are homologous 
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to their human counterparts, except for Ifi47. This observation suggests that some phenomena 
common to the tested animals and humans may be identified via the animal experiments by 
means of marker genes. To test this hypothesis and to develop an in vitro assay system, the use 
of human peripheral blood mononuclear cell-based or alveolar-epithelial-cell-based methods 
is necessary. Thus, extrapolation of the results of these evaluations to humans can be partially 
achieved by bridging the species differences with the marker genes.
11. Conclusions
It has been established that information that could not be obtained by conventional pheno-
typic analyses can be obtained by genomic analyses. Research conducted on the safety of 
vaccines and adjuvants using toxicogenomics has been less likely to be reported, and such 
data about chemically synthesized drugs have mostly been limited. Since the late 2000s, we 
have been trying to apply the genomics technology to the safety assessment of vaccines, 
and to demonstrate its sensitivity, ability to yield abundant toxicological and mechanistic 
information, the possibility of extrapolating its results to humans, and its potential for appli-
cation to in vitro evaluation systems. In addition, we have shown that the newly developed 
evaluation system may be employed in analyses involving a biomarker gene(s) as an indi-
cator, instead of the conventional quality control or safety test. It can also be assumed that 
these technologies can be utilized for adjuvant development, and it is expected that a wide 
range of genomics technologies will be applied in the future to the development of quality 
control and safety testing.
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